Wolfe Med Tools: The PODD-nundrum – Unpack Pump Industry Profit – Underappreciated Difference?

Research evidence excerpt

Wolfe Med Tools: The PODD-nundrum – Unpack Pump Industry Profit – Underappreciated Difference?

June 17, 2026

Wolfe Research, LLC Fundamental Recommendation, Rating and Target Price Risks:

Company: Risks That May Impede Achievement of the Recommendation, Rating or Target

Price:

Beta Bionics, Inc. Downside risks to the Outperform rating include slower and/or disappointing user

base growth due to increased competition and/or reduced ability for pumps to

increase type 1 market penetration, unforeseen pricing pressure on Beta's premium

price in the pharmacy channel, unforeseen quality issues and recalls, inability of

the pump segment to materially increase penetration in the type 2 market longer

term, disruption from new pharmaceutical options for diabetes over the long haul

including GLP1s, failure to launch products in R&D pipeline, and/or inability to

generate profit long term.

Medtronic Plc Upside risks to the Peer Perform rating include faster-than-expected ramps of

key long-term growth drivers like Hugo soft tissue robot and Symplicity renal

denervation system, better-than-expected core growth and margin expansion, and

capital deployment accretive to estimates beyond our share repurchase placeholder.

Downside risks to the Peer Perform rating include increased PFA competition ahead,

TAVR quality issues risking share position in that category, and dilution risk from

pending diabetes split.

Insulet Corporation Downside risks to the Outperform rating include slower and/or disappointing user

increase type 1 market penetration, unforeseen pricing pressure on Omnipod’s

premium US selling price, unforeseen quality issues and recalls, inability of the

pump segment to materially increase penetration in the type 2 market longer